T 세포 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global T-cell therapies market size is expected to reach USD 25.31 Billion in 2034 from USD 5.40 Billion in 2025, growing at a CAGR of 18.72% during 2026-2034.The Global T-Cell Therapies Market is experiencing rapid growth due to breakthroughs in immunotherapy. T-cell therapies, including CAR-T treatments, harness the immune system to target cancer cells. Rising prevalence of hematological malignancies is supporting market expansion.

Major growth drivers include increasing clinical trials and regulatory approvals for advanced therapies. Pharmaceutical and biotech companies are investing heavily in cell-based treatment innovation. Growing focus on personalized medicine is further strengthening demand. Additionally, supportive reimbursement frameworks in developed markets are encouraging adoption.

Future prospects remain strong as research expands into solid tumor applications. Emerging markets investing in advanced healthcare infrastructure will create new opportunities. Companies are focusing on scalable manufacturing and reduced treatment costs. As immunotherapy continues to evolve, the Global T-Cell Therapies Market is expected to witness substantial long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• CAR T-Cell Therapy
• T-Cell Receptor (TCR)-Based

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By End User

• Hospitals
• Cancer Treatment Centers

COMPANIES PROFILED

• Novartis, Gilead Sciences/Kite, Bristol Myers Squibb, Johnson & Johnson/Legend Biotech, Roche, Adaptimmune, Iovance Biotherapeutics, Autolus Therapeutics, Cellectis, Fate Therapeutics, Century Therapeutics, Arcellx, Caribou Biosciences, CRISPR Therapeutics, Allogene Therapeutics, Sana Biotechnology, Poseida Therapeutics, Immatics, TScan Therapeutics, Tmunity Therapeutics

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL T-CELL THERAPIES MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. CAR T-Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. T-Cell Receptor (TCR)-Based Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL T-CELL THERAPIES MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Acute Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL T-CELL THERAPIES MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL T-CELL THERAPIES MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL T-CELL THERAPIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis
  • 9.2.2 Gilead Sciences/Kite
  • 9.2.3 Bristol Myers Squibb
  • 9.2.4 Johnson & Johnson/Legend Biotech
  • 9.2.5 Roche
  • 9.2.6 Adaptimmune
  • 9.2.7 Iovance Biotherapeutics
  • 9.2.8 Autolus Therapeutics
  • 9.2.9 Cellectis
  • 9.2.10 Fate Therapeutics
  • 9.2.11 Century Therapeutics
  • 9.2.12 Arcellx
  • 9.2.13 Caribou Biosciences
  • 9.2.14 CRISPR Therapeutics
  • 9.2.15 Allogene Therapeutics
  • 9.2.16 Sana Biotechnology
  • 9.2.17 Poseida Therapeutics
  • 9.2.18 Immatics
  • 9.2.19 TScan Therapeutics
  • 9.2.20 Tmunity Therapeutics